samedan logo
 
 
spacer
home > ict > winter 2018 > protected and prepared
PUBLICATIONS
International Clinical Trials

Protected and Prepared

The European clinical research industry is in a period of great uncertainty. As it reckons with current trends – such as a decline in favourability as a clinical trial destination in favour of the Asia Pacific (APAC) region and other geographies – it is simultaneously bracing itself for other changes on the horizon. These upcoming changes are largely regulatory in nature; new regulations are related to advanced therapy medicinal products (ATMPs) and medical devices, which could both add and relieve headaches for researchers (1). Also, the new Clinical Trial Regulation is coming in 2019. Furthermore, after Brexit takes effect that same year, the UK may exempt itself from the Regulation, possibly creating complexities and uncertainties both there and in the post-Brexit EU (2).

Then there is the Greater Data Protection Regulation (GDPR): a vast set of rules and guidelines aimed largely at securing the personal data of EU citizens stored and processed online. While designed for the protection of Europeans, the effects of the GDPR are by no means limited to Europe: EU nationals anywhere in the world are protected by the new law – the personal data of a German citizen living and working in Australia, for example, would be covered – lending it significance on a global level. Given its breadth and its imminence (the law is set to take effect in May of this year), it behooves one to examine the context from which it emerged, as well as how the clinical research industry falls within its scope. Indeed, clinical research and the healthcare industry, at large – which stores massive quantities of personal data in formats such as electronic medical records and clinical trial databases – is bracing for the impact of the GDPR on its operations. What events set the stage for the GDPR, how will it affect Europe’s status as a clinical trial destination, and how can organisations ensure compliance?

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Mike Novotny is the founder and CEO of Medrio – a provider of cloud-based electronic data capture, eSource, and ePRO tools for clinical trials. Mike applies 20 years of experience in research and software to his eClinical Software-as-a-Service vision.

Nick O’Brien leads content marketing efforts at Medrio. At the company, he spearheads co-marketing initiatives, such as complimentary case studies with customers, and creates and commissions content for marketing campaigns. He brings years of experience in copywriting and blogging to his role and holds a BA from Kenyon College, US.

spacer
Mike Novotny
spacer
spacer
spacer
Nick O’Brien
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

HATRIC-based identification of receptors for orphan ligands (small molecules)

HATRIC-LRC (Ligand Receptor Capture) enables now the identification of small molecule targets on the surface of living cells! Even primary cells!
More info >>

White Papers

Clinical Trial Labelling – More Than Just Labels

Faubel & Co. Nachfolger GmbH

Deciding which label is best for a particular trial project is not always easy. Labels have become multifunctional tools which are able to convey variable data in different languages, indicate first opening, product originality, support ease of use or blind study drugs. They are no longer used as mere carriers of specified contents.
More info >>

 
Industry Events

Automatica 2018

18 June 2018, Messe München, Munich, Germany

Automatica is the leading exhibition for smart automation and robotics. It features the world's largest range of robotics, assembly systems, machine vision systems and components. For more information go to automatic-munich.com/visitors
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement